Novartis India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve the Letter of Offer and intimation of the Rights Issue Committee Meeting to decide and discuss, matters in connection with the Rights Issue.

Evonile Pharma Limited (formerly known as Novartis India Limited) November 01, 2026 The Secretary, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001. Scrip Code: 500672 Sub: Disclosure regarding the receipt of In-Principle Approval and prior intimation under Regulation 29(1)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 of the proposed meeting of the Board of Directors of Evonile Pharma Limited (formerly known as Novartis India Limited) (the “Company”) to be held on November 04, 2026. This is further to our intimation dated October 08, 2026, about the approval accorded by the Board of Directors of the Company for the issuance of partly paid up equity shares of the Company by way of a rights issue ("Rights Issue" and such equity shares, “Rights Equity Shares”) to the eligible equity shareholders of the Company for an aggregate amount not exceeding ₹9,000.00 million (Rupees Nine Thousand Million only). We are pleased to inform you that our Company has received the in-principle approval of BSE Limited (the “Stock Exchange”), on October 30, 2026, for the proposed Rights Issue. Accordingly, in accordance with the requirements of Regulation 29(1)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we wish to intimate you that the meeting of (i) the Board of Directors is scheduled to be held on November 04, 2026 to inter alia consider and approve the Letter of Offer in connection with the Rights Issue; and (ii) the Rights Issue Committee is proposed to be held on November 04, 2026 to inter alia consider, decide and discuss, matters in connection with the Rights Issue, including the determination of issue price, entitlement ratio, record date, fractional entitlement etc., among others. Kindly take the above on record. Thanking You, For Evonile Pharma Limited (Formerly known as Novartis India Limited) Chandni Maru Company Secretary and Compliance Officer A60291 Encl: as above Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@evonilepharma.com | Website: www.evonilepharma.com